Sangamo BioSciences (NASDAQ:SGMO): The mean short term price target for Sangamo BioSciences (NASDAQ:SGMO) has been established at $18.4 per share. The higher price target estimate is at $30 and the lower price target estimate is expected at $14 according to 5 Analyst. The stock price is expected to vary based on the estimate which is suggested by the standard deviation value of $6.58
For this week, the average consensus of the company shares are rated as a Strong Buy.
On the companys insider trading activities, The Securities and Exchange Commission has divulged that Lanphier Edward O Ii, director officer (President & CEO) of Sangamo Biosciences Inc, had unloaded 25,000 shares at an average price of $10.43 in a transaction dated on July 15, 2015. The total value of the transaction was worth $260,750.
Sangamo BioSciences (NASDAQ:SGMO) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.21 points or 3.26% at $6.23 with 958,663 shares getting traded. Post opening the session at $6.39, the shares hit an intraday low of $6.16 and an intraday high of $6.51 and the price was in this range throughout the day. The company has a market cap of $439 million and the number of outstanding shares have been calculated to be 70,492,496 shares. The 52-week high of Sangamo BioSciences (NASDAQ:SGMO) is $11.9293 and the 52-week low is $4.63.
Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research development and commercialization of engineered DNA-binding proteins as therapeutic products. The main focus for the Company is the development of novel human therapeutics and it is building a pipeline of ZFP Therapeutics. The Companys lead ZFP Therapeutic SB-728-T, a ZFN-modified autologous T-cell product is under development for the treatment of HIV/AIDS. The Companys clinical stage programs also include SB-728-HSPC for the treatment of HIV/AIDS, SB-BCLmR-HSPC to treat Beta-thalassemia major and CERE-110 for the treatment of Alzheimers disease. Its pre-clinical products include SB-913 for the treatment of Hunter Syndrome and SB-318 for the treatment of Hurler Syndrome.